These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 24357461)
1. Macrophage-mediated glucolipotoxicity via myeloid-related protein 8/toll-like receptor 4 signaling in diabetic nephropathy. Kuwabara T; Mori K; Mukoyama M; Kasahara M; Yokoi H; Nakao K Clin Exp Nephrol; 2014 Aug; 18(4):584-92. PubMed ID: 24357461 [TBL] [Abstract][Full Text] [Related]
2. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Kuwabara T; Mori K; Mukoyama M; Kasahara M; Yokoi H; Saito Y; Ogawa Y; Imamaki H; Kawanishi T; Ishii A; Koga K; Mori KP; Kato Y; Sugawara A; Nakao K Diabetologia; 2012 Aug; 55(8):2256-66. PubMed ID: 22610400 [TBL] [Abstract][Full Text] [Related]
3. Ablation of Myeloid Cell MRP8 Ameliorates Nephrotoxic Serum-induced Glomerulonephritis by Affecting Macrophage Characterization through Intraglomerular Crosstalk. Hata Y; Kuwabara T; Mori K; Kan Y; Sato Y; Umemoto S; Fujimoto D; Kanki T; Nishiguchi Y; Yokoi H; Kakizoe Y; Izumi Y; Yanagita M; Mukoyama M Sci Rep; 2020 Feb; 10(1):3056. PubMed ID: 32080297 [TBL] [Abstract][Full Text] [Related]
4. Predictive significance of kidney myeloid-related protein 8 expression in patients with obesity- or type 2 diabetes-associated kidney diseases. Kuwabara T; Mori K; Kasahara M; Yokoi H; Imamaki H; Ishii A; Koga K; Sugawara A; Yasuno S; Ueshima K; Morikawa T; Konishi Y; Imanishi M; Nishiyama A; Nakao K; Mukoyama M PLoS One; 2014; 9(2):e88942. PubMed ID: 24558454 [TBL] [Abstract][Full Text] [Related]
5. Globo-series glycosphingolipids enhance Toll-like receptor 4-mediated inflammation and play a pathophysiological role in diabetic nephropathy. Nitta T; Kanoh H; Inamori KI; Suzuki A; Takahashi T; Inokuchi JI Glycobiology; 2019 Mar; 29(3):260-268. PubMed ID: 30476082 [TBL] [Abstract][Full Text] [Related]
6. MiR-874 alleviates renal injury and inflammatory response in diabetic nephropathy through targeting toll-like receptor-4. Yao T; Zha D; Gao P; Shui H; Wu X J Cell Physiol; 2018 Jan; 234(1):871-879. PubMed ID: 30171701 [TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase. Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641 [TBL] [Abstract][Full Text] [Related]
8. Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Mallipattu SK; Gallagher EJ; LeRoith D; Liu R; Mehrotra A; Horne SJ; Chuang PY; Yang VW; He JC Am J Physiol Renal Physiol; 2014 May; 306(9):F1008-17. PubMed ID: 24598803 [TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Liang G; Song L; Chen Z; Qian Y; Xie J; Zhao L; Lin Q; Zhu G; Tan Y; Li X; Mohammadi M; Huang Z Kidney Int; 2018 Jan; 93(1):95-109. PubMed ID: 28750927 [TBL] [Abstract][Full Text] [Related]
10. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Verzola D; Cappuccino L; D'Amato E; Villaggio B; Gianiorio F; Mij M; Simonato A; Viazzi F; Salvidio G; Garibotto G Kidney Int; 2014 Dec; 86(6):1229-43. PubMed ID: 24786705 [TBL] [Abstract][Full Text] [Related]
11. Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophages. Wang J; Vodovotz Y; Fan L; Li Y; Liu Z; Namas R; Barclay D; Zamora R; Billiar TR; Wilson MA; Fan J; Jiang Y FASEB J; 2015 Jan; 29(1):250-62. PubMed ID: 25342131 [TBL] [Abstract][Full Text] [Related]
12. Platelet-neutrophil interaction aggravates vascular inflammation and promotes the progression of atherosclerosis by activating the TLR4/NF-κB pathway. Liang X; Xiu C; Liu M; Lin C; Chen H; Bao R; Yang S; Yu J J Cell Biochem; 2019 Apr; 120(4):5612-5619. PubMed ID: 30302814 [TBL] [Abstract][Full Text] [Related]
13. Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Devaraj S; Tobias P; Jialal I Cytokine; 2011 Sep; 55(3):441-5. PubMed ID: 21498084 [TBL] [Abstract][Full Text] [Related]
14. Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. Yonekawa K; Neidhart M; Altwegg LA; Wyss CA; Corti R; Vogl T; Grigorian M; Gay S; Lüscher TF; Maier W Atherosclerosis; 2011 Oct; 218(2):486-92. PubMed ID: 21782178 [TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. Lin M; Yiu WH; Wu HJ; Chan LY; Leung JC; Au WS; Chan KW; Lai KN; Tang SC J Am Soc Nephrol; 2012 Jan; 23(1):86-102. PubMed ID: 22021706 [TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory effects of 1,25-dihydroxyvitamin D3 in monocytes cultured in serum from patients with type 2 diabetes mellitus and diabetic nephropathy with uremia via Toll-like receptor 4 and nuclear factor-κB p65. Yang M; Xu J; Yu J; Yang B; Gan H; Li S; Li X Mol Med Rep; 2015 Dec; 12(6):8215-22. PubMed ID: 26497229 [TBL] [Abstract][Full Text] [Related]
17. Expression and cellular distribution of TLR4, MyD88, and NF-κB in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo. Liu P; Li F; Qiu M; He L Diabetes Res Clin Pract; 2014 Aug; 105(2):206-16. PubMed ID: 24894085 [TBL] [Abstract][Full Text] [Related]
18. Global Toll-like receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy. Jialal I; Major AM; Devaraj S J Diabetes Complications; 2014; 28(6):755-61. PubMed ID: 25116192 [TBL] [Abstract][Full Text] [Related]
19. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Ma J; Wu H; Zhao CY; Panchapakesan U; Pollock C; Chadban SJ Int J Clin Exp Pathol; 2014; 7(2):481-95. PubMed ID: 24551269 [TBL] [Abstract][Full Text] [Related]
20. Suppression of TLR4 by miR-448 is involved in Diabetic development via regulating Macrophage polarization. Zhao Q; Wang X; Hu Q; Zhang R; Yin Y J Pharm Pharmacol; 2019 May; 71(5):806-815. PubMed ID: 30536833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]